using mrd and pet/ct to assess responses post-asct in myeloma
Published 3 years ago • 57 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
2:33
an update on antibody-based treatment approaches in multiple myeloma
-
0:55
the significance of cr as an endpoint in frail patients with multiple myeloma
-
0:59
the treatment of patients with t(11;14) myeloma
-
1:23
managing patients with multiple myeloma who have stopped treatment prior to relapse
-
1:18:54
jtmp webinar: hematology - the royal disease
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
5:54
redirectt-1 results: teclistamab talquetamab in r/r multiple myeloma
-
3:01
treatment approaches for asct-eligible myeloma patients in the frontline
-
0:42
talquetamab treatment in patients with r/r myeloma with prior exposure to t-cell-directed therapies
-
1:37
mrd in myeloma
-
2:31
stem cell collection in patients with multiple myeloma treated with anti-cd38 monoclonal antibodies
-
3:06
phase i study of hpn217 in patients with r/r multiple myeloma
-
0:50
the expanding therapeutic landscape of r/r multiple myeloma
-
0:46
2-year follow-up of majestec-1: teclistamab in r/r multiple myeloma
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
2:30
a new era of treatment for multiple myeloma
-
1:45
targetting bcma in myeloma
-
4:27
antibody-based targeting of bcma in multiple myeloma
-
1:44
optimal treatment sequencing in multiple myeloma
-
1:36
the relevance of sct in multiple myeloma
-
1:53
the future of multiple myeloma treatment